Genprex Inc
Change company Symbol lookup
Select an option...
GNPX Genprex Inc
GBTC Grayscale Bitcoin Trust (BTC)
F Ford Motor Co
SNEX Stonex Group Inc
BGCP BGC Partners Inc
ANIP ANI Pharmaceuticals Inc
SMG Scotts Miracle-Gro Co
CODX Co-Diagnostics Inc
LQDA Liquidia Technologies Inc
VSLR Vivint Solar Inc
Go

Health Care : Biotechnology |
Company profile

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Closing Price
$3.15
Day's Change
0.12 (3.96%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.20
Day's Low
3.01
Volume
(Light)
Volume:
1,081,196

10-day average volume:
2,133,161
1,081,196

Upcoming Events

GNPX's fiscal year ends in December
There are no upcoming events for GNPX

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
May 14, 2020Q1 2020 Earnings Release-$0.20-$0.08 to -$0.08-$0.14
August 13, 2019Q2 2019 Earnings Release-$0.24-$0.21 to -$0.21--

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.